CAU
NUVB icon

Caxton Associates (UK)’s Nuvation Bio NUVB Stock Holding History

Caxton Associates (UK)’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$205K Sell
47,827
-537,108
-92% -$2.99M ﹤0.01% 718
2025
Q4 		$5.24M Buy
584,935
+392,650
+204% +$2.43M 0.1% 62
2025
Q3 		$711K Buy
+192,285
New +$524K 0.02% 399

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Caxton Associates (UK)'s NUVB Position: Q1 2026 in Review

Caxton Associates (UK) reduced its Nuvation Bio (NUVB) stake by 92% in Q1 2026, selling an estimated $2.99M and leaving 47,827 shares worth $205K. The position accounts for ﹤0.01% of the portfolio, ranked #718.

Caxton Associates (UK) first reported a position in NUVB in Q3 2025 and has held it in 3 quarters since. The position peaked at $5.24M in Q4 2025. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • Caxton Associates (UK) held 47,827 shares of Nuvation Bio worth $205K as of Q1 2026.
  • Caxton Associates (UK) sold 537,108 Nuvation Bio shares in Q1 2026, an estimated $2.99M.
  • Nuvation Bio made up ﹤0.01% of Caxton Associates (UK)'s portfolio in Q1 2026, its #718 holding.
  • Caxton Associates (UK) first reported a position in Nuvation Bio in Q3 2025 and has held it in 3 quarters since.
  • Caxton Associates (UK)'s Nuvation Bio position peaked at $5.24M in Q4 2025.
  • 231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.